Top 10 Companies in the Global Glycan Biosynthesis Market (2026): Market Leaders Driving Biopharma Innovation

MARKET INSIGHTS

Global glycan biosynthesis market was valued at USD 850 million in 2024, with projections indicating growth to USD 1.54 billion by 2032, at a compound annual growth rate (CAGR) of 8.3% during the forecast period. This expansion is driven by increasing applications in biologics development and rising demand for glycan-based therapeutics.

Glycan biosynthesis involves enzymatic processes that create complex carbohydrate structures essential for biological functions, including cell signaling, immune response modulation, and protein folding. Key glycan types include N-glycans (attached to asparagine residues) and O-glycans (linked to serine/threonine), which are critical in biopharmaceutical quality control and disease biomarker discovery.

Market growth is fueled by several factors: the expanding biopharmaceutical sector, increasing research into glycan-based vaccines (particularly for cancer immunotherapy), and technological advancements in glycan analysis tools. Notably, in Q1 2024, Creative Biolabs launched a novel high-throughput glycan synthesis platform, accelerating drug discovery timelines. However, challenges persist in standardization and scalability of glycan production methods. Leading players like Asparia Glycomics and Medicinal Chemistry Pharmaceuticals are investing heavily in enzymatic synthesis technologies to address these bottlenecks.

Global Glycan Biosynthesis Market – View in Detailed Research Report

Market size: The market was valued at USD 850 million in 2024 and is projected to reach USD 1.54 billion by 2032, reflecting a steady upward trajectory as biopharmaceutical demand rises.

Product definition: Glycan biosynthesis refers to the enzymatic creation of complex carbohydrate chains that modulate protein function, immune recognition, and cell signaling, thereby underpinning therapeutic protein development and disease biomarker discovery.

🔟 10. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Glycosylation analysis platforms, therapeutic glycan synthesis, and biopharmaceutical support services

Merck KGaA has positioned itself at the forefront of glycan technology by integrating high‑resolution mass spectrometry with automated synthesis modules, enabling rapid characterization of glycoforms in biologics. The company’s investment in glycan‑focused research centers and its partnership with leading vaccine developers underscore its commitment to expanding the therapeutic portfolio of glycan‑engineered products.

Growth Initiatives:

• Expansion of glycan analytics suite for biologics quality control
• Strategic collaborations with academic glycobiology institutes
• Investment in AI‑driven glycan profiling algorithms

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🗹 9. Lectenz Bio

Headquarters: San Diego, California, USA
Key Offering: Custom glycan synthesis, glycan library development, and analytical services

Lectenz Bio’s proprietary synthesis platform allows rapid production of defined glycan structures, facilitating the design of glyco‑engineered biologics with tailored pharmacokinetics. By providing comprehensive glycan libraries, the company supports drug discovery programs across oncology, immunology, and rare disease sectors.

Growth Initiatives:

• Launch of a cloud‑based glycan design tool for partner companies
• Partnerships with major biopharma firms to co‑develop glycan‑modified therapeutics
• Expansion into the diagnostics market with glycan‑based biomarker panels

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🕘 8. Z Biotech, LLC

Headquarters: Austin, Texas, USA
Key Offering: Automated glycan synthesis instruments and analytical workflows

Z Biotech’s flagship platform integrates microfluidic synthesis with real‑time mass spectrometry, reducing production costs by up to 40% and enabling scalable glycan manufacturing for biologics and vaccine candidates.

Growth Initiatives:

• Strategic alliance with a leading vaccine developer for glycan‑based immunogens
• Expansion of service‑based analytics for academic and contract research organizations
• Investment in AI‑driven predictive models for glycosylation outcomes

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

📈 7. Summit Therapeutics

Headquarters: London, United Kingdom
Key Offering: Glycan‑engineered therapeutic proteins and vaccine platforms

Summit Therapeutics focuses on integrating glycan engineering into antibody‑drug conjugates and viral vector design, aiming to improve efficacy and reduce immunogenicity. The company’s pipeline includes glyco‑modified monoclonal antibodies for oncology and rare diseases.

Growth Initiatives:

• Partnerships with global pharma to co‑develop glycan‑enhanced biologics
• Investment in next‑generation synthesis robots
• Expansion of diagnostics arm to offer glycan‑based liquid biopsy kits

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🛠 6. Thermo Fisher Scientific

Headquarters: Waltham, Massachusetts, USA
Key Offering: Comprehensive glycan analysis instruments and reagents

Thermo Fisher’s portfolio includes high‑throughput LC‑MS platforms, glycan labeling kits, and software solutions that streamline glycosylation profiling for biopharmaceutical developers, accelerating the path from discovery to market.

Growth Initiatives:

• Launch of an integrated glycan analytics workflow for contract research organizations
• Strategic acquisition of a leading glycan synthesis startup to broaden platform capabilities
• Expansion of training programs for glycoscience professionals

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

⚙ 5. Danaher Corporation

Headquarters: Dublin, Ireland (global operations)
Key Offering: Glycan analysis instrumentation and integrated workflows via Beckman Coulter

Danaher’s acquisition of Beckman Coulter has enabled the company to offer end‑to‑end glycan analysis solutions, from sample preparation to data interpretation, supporting biopharmaceutical manufacturers in meeting stringent regulatory standards.

Growth Initiatives:

• Expansion of global distribution networks for glycan analytics kits
• Collaboration with academic institutions to develop next‑generation mass spectrometry modules
• Investment in cloud‑based data analytics for glycan profiling

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🧬 4. Bio-Techne Corporation

Headquarters: Minneapolis, Minnesota, USA
Key Offering: Glycan reagents, labeling kits, and analytical tools

Bio-Techne supplies a broad range of glycan reagents that enable precise modification of therapeutic proteins, facilitating the development of next‑generation biologics with optimized pharmacokinetic profiles.

Growth Initiatives:

• Launch of a modular glycan labeling platform for high‑throughput screening
• Strategic partnership with a leading vaccine manufacturer to explore glycan‑enhanced immunogens
• Expansion of training and certification programs for glycoscience researchers

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🚀 3. Creative Biolabs

Headquarters: Austin, Texas, USA
Key Offering: High‑throughput glycan synthesis platform and analytical services

Creative Biolabs’ recent launch of a novel high‑throughput synthesis platform in Q1 2024 has accelerated the pace of glycan‑driven drug discovery, enabling researchers to generate complex glycan libraries in weeks rather than months.

Growth Initiatives:

• Expansion of global service footprint to support biopharma and academic labs
• Development of AI‑powered glycan design tools for therapeutic optimization
• Strategic alliances with contract research organizations for rapid prototyping

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🔬 2. Asparia Glycomics

Headquarters: Barcelona, Spain
Key Offering: O‑glycan synthesis technologies and therapeutic glycan engineering

Asparia Glycomics specializes in the enzymatic synthesis of O‑glycans for therapeutic applications, providing a scalable platform that delivers high‑purity glycans for biologics and vaccine development.

Growth Initiatives:

• Strategic partnership with a major pharmaceutical company for cancer biomarker development
• Investment in next‑generation enzymatic reactors to increase throughput
• Expansion of global distribution network for glycan synthesis kits

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🧪 1. Medicinal Chemistry Pharmaceuticals

Headquarters: Madrid, Spain
Key Offering: Comprehensive glycobiology solutions, including synthesis, analysis, and quality control for biologics

Medicinal Chemistry Pharmaceuticals has established itself as a leader in glycan technology through its integrated platform that spans from raw material synthesis to final product characterization, supporting the development of glycan‑engineered biologics with improved therapeutic properties.

Growth Initiatives:

• Expansion of its glycan analytics suite to cover emerging therapeutic modalities
• Strategic collaborations with academic centers to accelerate glycan research
• Investment in AI‑based predictive tools for glycosylation pattern optimization

Download FREE Sample Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

---

Get Full Report: Global Glycan Biosynthesis Market – View in Detailed Research Report

🌍 Outlook: The Future of Glycan Biosynthesis

As the biopharmaceutical landscape continues to evolve, glycan biosynthesis is set to become a cornerstone of next‑generation therapeutics. The integration of automated synthesis, AI‑driven design, and high‑throughput analytics is expected to reduce development timelines and lower costs, thereby expanding access to glycan‑based drugs across oncology, immunology, and rare disease sectors.

📊 Key Trends Shaping the Market

• Rapid adoption of enzymatic synthesis platforms for scalable production.
• Growing emphasis on glycan‑modified biologics to enhance efficacy and reduce immunogenicity.
• Expansion of diagnostic applications using glycan biomarkers for early disease detection.
• Strategic partnerships between academia and industry accelerating technology transfer.
• Increased regulatory focus on glycosylation characterization, driving standardization efforts.

🚀 Future Trends

Emerging areas such as cell and gene therapy, synthetic glycans for precision medicine, and AI‑enhanced glycan engineering are poised to create new growth avenues. Companies that invest in integrated platforms—combining synthesis, analysis, and data science—will be best positioned to capture the expanding market share and deliver innovative therapies to patients worldwide.